Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

EVAMIST Drug Profile

« Back to Dashboard

Which patents cover Evamist, and what substitute generic drugs are available?

Evamist is a drug marketed by Elan Pharma Intl Ltd and is included in one NDA. There are four patents protecting this drug.

This drug has fifty patent family members in seventeen countries.

The generic ingredient in EVAMIST is estradiol. There are seventy-five drug master file entries for this compound. Forty-eight suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the estradiol profile page.

Summary for Tradename: EVAMIST

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list63
Patent Applications: see list9,760
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:EVAMIST at DailyMed

Pharmacology for Tradename: EVAMIST

Ingredient-typeEstradiol Congeners
Drug ClassEstrogen
Mechanism of ActionEstrogen Receptor Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes6,299,900► SubscribeY ► Subscribe
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes6,978,945► SubscribeY ► Subscribe
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes6,818,226► SubscribeY ► Subscribe
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYesYes6,923,983► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EVAMIST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 20076,818,226► Subscribe
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 20076,299,900► Subscribe
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 20076,923,983► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: EVAMIST

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,438,203Dermal penetration enhancers and drug delivery systems involving same► Subscribe
6,916,486 Transdermal delivery of analgesics► Subscribe
6,998,138Topical delivery of anti-alopecia agents► Subscribe
7,094,422Topical delivery of antifungal agents► Subscribe
7,387,789Transdermal delivery of non-steroidal anti-inflammatory drugs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EVAMIST

Country Document Number Estimated Expiration
Luxembourg91972► Subscribe
New Zealand538322► Subscribe
AustraliaPN814496► Subscribe
Hong Kong1087355► Subscribe
Hungary0302569► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EVAMIST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
2016 00016Denmark► SubscribePRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
/2004Austria► SubscribePRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
00523Netherlands► SubscribePRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc